Specialty Pharmacy

Top news of the day from across the health care landscape.

Juluca is indicated as a complete therapy for patients with HIV-1.

The National Association of Specialty Pharmacy plans to submit comments about proposed Medicare changes.

Many immunotherapy clinical trials exclude HIV-positive patients with cancer.

The #APharmacistIs campaign demonstrates the value of pharmacists in improving the lives of patients.

Multiple mutations may work together to develop drug-resistant non-small cell lung cancer.

Guidelines suggest that patients with endocrine intestinal tumors should undergo surgery.

Top news of the day from across the health care landscape.

HIV-positive patients need to maintain healthy body weight, quit smoking, eat well, exercise regularly and treat hypertension, diabetes and dyslipidemia.

Customized technology may help specialty pharmacies drive adherence and patient outcomes.

Cetuximab-based imaging can detect brain cancer tumors as small as 10-mg.

Jonathan Ogurchak, PharmD, CSP, vice president of Business Operations at PANTHERx Specialty Pharmacy, discusses the importance of disruption.

Top news of the day from across the health care landscape.

A cancer diagnosis in young patients can cause post-traumatic stress disorder that can persist long afterwards.

Doubling Medicare sequester cuts could reduce access to lower-cost cancer treatment.

Ron Lanton III, Esq, president, True North Political Solutions, LLC, takes a legal perspective on direct and indirect remuneration fees and how they affect specialty pharmacies.

Only 15% of patients with a 20% to 24% risk of breast cancer received a recommended MRI screening.

The FDA created a framework to create safe and effective regenerative medicine products.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the healthcare landscape.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Sunitinib malate (Sutent) is an adjuvant therapy for adults at risk of recurrent renal cell carcinoma following nephrectomy.

Sunitinib malate (Sutent) may improve disease-free survival among patients with renal cell carcinoma.

Emicizumab-kxwh (Hemlibra) demonstrated the ability to reduce bleeding events that require treatment in patients with hemophilia A.

Fulvestrant (Faslodex) plus abemaciclib may improve progression-free survival among patients with advanced or metastatic breast cancer.

Benralizumab (Fasenra) demonstrates the ability to significantly deplete eosinophils and could reduce the need for oral steroid use.

Fallopian tube lesions may be the precursor to high-grade serious ovarian carcinoma.

Fully understanding a patient's genes may help physicians treat rheumatic diseases.